updat model upsid
downgrad neutral track
downgrad neutral rais target price downgrad
neutral outperform follow syk announc pend deal rais
price target in-lin term deal expect wmgi
stock perform next twelv month driven deal price
fundament overal view deal syk perspect make
strateg sens significantli enhanc syk extrem portfolio improv syk
market share shoulder foot ankl market posit compani
launch success mako robot surgeri applic shoulder elbow
basi wmgi formerli tornier market-lead shoulder portfolio
upper lower extrem estim org vs cse
cartiva sale exceed estim guidanc management clear import
hurdl deliv upsid estim difficult includ stabil
cartiva sale quarter came slightli ahead guidanc
estim compani provid reconcili non-gaap ep
therefor apples-to-appl comparison difficult said expect upsid
non-gaap earn direct consist upsid report sale result
compet offer rel unlik see compet bid
rel unlik given small number potenti acquir premium
paid novemb close price said sn past express gener
interest extrem ortho histor preced compani make
compet offer announc deal segment privat equiti consortium
announc offer take biomet privat howev given new ceo sn
novemb premium paid think could less like compani
opt step
chang model rais revenu ep estim slightli base
upsid result averag beyond
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
rate outperform neutral
wright medic global manufactur provid medic devic
equip treatment musculoskelet disord
emphasi upper lower extrem
target price base compet bid
repres premium offer
grey target price base deal fall
stock revert back close price deal rumor
publish press
 close
addit detail takeaway
cc vs cse
 upper extrem primarili driven on-going launch flex reviv
revis shoulder system on-going adopt blueprint perform revers glenoid system
simplic shoulder system ou sale primarili driven growth direct
lower extrem million mil y/i
cc vs cse
 lower extrem primarili driven cartiva net sale mil
vs mil ou sale growth primarili driven increas sale volum
stock distributor cartiva sale mil in-lin biolog mil
 sale driven volum growth core biolog product augment inject
ou sale decreas due time sale stock distributor
 review upsid margin ep beat estim
adj ebitda margin bp estim sale net cog
non-op incom partial off-set sg deliv net loss
better estim note compani provid non-gaap
reconcili file therefor analysi incorpor
note compani provid non-gaap reconcili file therefor
analysi incorpor estim non-gaap adjust
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto novemb
chang model
rais revenu ep estim slightli base upsid
result beyond increas sale estim averag
increas ep estim year
figur chang model
price base current valu pend deal previou target
price base ev/sal multipl ntm sale bil risk sale
product product delay failur achiev long term goal litig regulatory/qu
issu disrupt deal close
basic propos acquisit
novemb market open announc definit agreement acquir
issu outstand ordinari share total equiti valu
bil total enterpris valu bil board compani
approv transact deal expect close management expect deal
neutral ep assum sept close dilut accret
thereaft expect mil cost synergi major expect
achiev first three year post close start driven share servic
ration back-offic qualiti manufactur
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
